Drug Price Trends for ELETRIPTAN HBR

Average Pharmacy Cost for ELETRIPTAN HBR

These are average pharmacy acquisition costs (net of discounts) from a US national survey

Drug Name	NDC	Price/Unit ($)	Unit	Date
ELETRIPTAN HBR 40 MG TABLET	68382-0923-86	2.17312	EACH	2024-12-18
ELETRIPTAN HBR 20 MG TABLET	00093-8310-18	2.05810	EACH	2024-12-18
ELETRIPTAN HBR 20 MG TABLET	00093-8310-19	2.05810	EACH	2024-12-18
ELETRIPTAN HBR 20 MG TABLET	00378-4287-85	2.05810	EACH	2024-12-18

Market Analysis and Price Projections for Eletriptan HBR

Introduction to Eletriptan HBR

Eletriptan, marketed under the brand name Relpax, is a second-generation triptan drug developed by Pfizer Inc. for the treatment of migraine headaches. It belongs to the class of selective serotonin receptor agonists, specifically targeting 5-HT1B, 5-HT1D, and 5-HT1F receptors to alleviate migraine symptoms[1].

Market Size and Growth Projections

The global eletriptan market has been experiencing steady growth, driven by several key factors. As of 2023, the market size was valued at approximately $105 million and is projected to reach $109.31 million in 2024. By 2032, the market is expected to grow to $147.6 million, exhibiting a Compound Annual Growth Rate (CAGR) of 4.1% during the forecast period[2].

Another report indicates that the global eletriptan market size was valued at $108 million in 2023 and is forecasted to reach $141.4 million by 2030, with a CAGR of 3.9% during the review period[5].

Drivers of Market Growth

Several factors are driving the growth of the eletriptan market:

• Increasing Prevalence of Migraines: The rising prevalence of migraines worldwide is a significant driver. As awareness and understanding of migraines increase, so does the demand for effective treatments like eletriptan[5].
• Targeted Treatment: Eletriptan's targeted approach, acting on specific serotonin receptors, makes it an effective and preferred treatment for migraines[5].
• Healthcare Expenditure and Access: Improving healthcare infrastructure in emerging economies increases the availability and awareness of migraine treatments, driving market growth[5].
• Patent Expirations: The expiration of patents for certain migraine medications leads to the introduction of more generic versions, potentially lowering prices and increasing competition, which can benefit the eletriptan market[5].

Market Segmentation

The eletriptan market is segmented based on several criteria:

• Type: The market is segmented into 20mg and 40mg tablets. These dosages are available in various settings, including hospitals and drug stores[2][5].
• Applications: The primary applications are in hospitals and drug stores. The report provides detailed data on sales quantities and consumption values by application[5].
• Regions: The market is analyzed regionally, with North America and Europe showing steady growth driven by government initiatives and increasing consumer awareness. The Asia-Pacific region, particularly China, leads the global market due to robust domestic demand and supportive policies[5].

Economic Analysis and Cost-Effectiveness

Economic analyses have shown that eletriptan is one of the most cost-effective triptan therapies for treating migraines. A pharmacoeconomic study revealed that eletriptan 20mg and 40mg doses were associated with the lowest cost to treat 100 migraine attacks and the lowest cost per successfully treated patient. Specifically, eletriptan 40mg had the lowest cost/success, ranging from $57.03 to $60.05, compared to other triptans like naratriptan and sumatriptan[3].

Price Projections

The average price of eletriptan is expected to fluctuate based on market dynamics and regional variations. Here are some key points regarding price projections:

• Current Pricing: The current average price of eletriptan varies by type and application. For instance, the average price by type for the period 2019-2024 and 2025-2030 is detailed in market reports[5].
• Future Projections: The global eletriptan average price by type and application is expected to stabilize or slightly decrease due to increased competition from generic versions and market expansion. For example, the average price by application from 2019 to 2030 is provided in detailed tables within market reports[5].

Competitive Landscape

The global eletriptan market is competitive, with several key players contributing to its growth. The report provides a dashboard overview of leading companies, including their marketing strategies, market share, and recent developments. Companies are focusing on effective marketing tactics and technological innovations to maintain their market position[2][4].

Regional Analysis

• North America and Europe: These regions are experiencing steady growth driven by government initiatives and increasing consumer awareness.
• Asia-Pacific: This region, particularly China, is leading the global market due to robust domestic demand, supportive policies, and a strong manufacturing base[5].

Key Takeaways

• Market Growth: The eletriptan market is projected to grow significantly, driven by the increasing prevalence of migraines and the effectiveness of the drug.
• Cost-Effectiveness: Eletriptan is one of the most cost-effective triptan therapies for treating migraines.
• Market Segmentation: The market is segmented by type, application, and region, with detailed data available for each segment.
• Price Projections: Prices are expected to stabilize or slightly decrease due to increased competition and market expansion.
• Competitive Landscape: The market is competitive, with key players focusing on effective marketing and technological innovations.

FAQs

What is eletriptan used for?

Eletriptan is used for the treatment of acute migraine headaches. It is a selective serotonin receptor agonist that targets 5-HT1B, 5-HT1D, and 5-HT1F receptors to alleviate migraine symptoms[1].

What are the common dosages of eletriptan?

The common dosages of eletriptan are 20mg and 40mg tablets, available in various settings such as hospitals and drug stores[2][5].

How cost-effective is eletriptan compared to other triptans?

Eletriptan is one of the most cost-effective triptan therapies. It has the lowest cost to treat 100 migraine attacks and the lowest cost per successfully treated patient, especially the 40mg dose[3].

What are the key drivers of the eletriptan market growth?

The key drivers include the increasing prevalence of migraines, the targeted and effective treatment offered by eletriptan, improving healthcare infrastructure in emerging economies, and the introduction of generic versions due to patent expirations[5].

Which regions are leading the global eletriptan market?

The Asia-Pacific region, particularly China, is leading the global market due to robust domestic demand, supportive policies, and a strong manufacturing base. North America and Europe are also experiencing steady growth[5].

Sources

1. DrugBank Online: Eletriptan: Uses, Interactions, Mechanism of Action.
2. OpenPR: Eletriptan Market Size In 2024 (New Report) Revenue to Cross 147.6 million by 2032.
3. PubMed: Economic analysis of triptan therapy for acute migraine.
4. Absolute Reports: Global Eletriptan Market.
5. Global Info Research: Global Eletriptan Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030.